- Home
- APVO vs ENSC Comparison
APVO vs ENSC Comparison
Compare APVO & ENSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APVO
- ENSC
- Stock Information
- Founded
- APVO 2016
- ENSC 2003
- Country
- APVO United States
- ENSC United States
- Employees
- APVO N/A
- ENSC N/A
- Industry
- APVO Biotechnology: Pharmaceutical Preparations
- ENSC Biotechnology: Pharmaceutical Preparations
- Sector
- APVO Health Care
- ENSC Health Care
- Exchange
- APVO Nasdaq
- ENSC Nasdaq
- Market Cap
- APVO 4.1M
- ENSC 3.4M
- IPO Year
- APVO N/A
- ENSC N/A
- Fundamental
- Price
- APVO $4.95
- ENSC $2.38
- Analyst Decision
- APVO Strong Buy
- ENSC
- Analyst Count
- APVO 1
- ENSC 0
- Target Price
- APVO $5,920.00
- ENSC N/A
- AVG Volume (30 Days)
- APVO 393.8K
- ENSC 455.1K
- Earning Date
- APVO 05-14-2025
- ENSC 05-13-2025
- Dividend Yield
- APVO N/A
- ENSC N/A
- EPS Growth
- APVO N/A
- ENSC N/A
- EPS
- APVO N/A
- ENSC N/A
- Revenue
- APVO N/A
- ENSC $6,224,081.00
- Revenue This Year
- APVO N/A
- ENSC N/A
- Revenue Next Year
- APVO N/A
- ENSC $1,381.48
- P/E Ratio
- APVO N/A
- ENSC N/A
- Revenue Growth
- APVO N/A
- ENSC 256.35
- 52 Week Low
- APVO $4.30
- ENSC $1.62
- 52 Week High
- APVO $658.60
- ENSC $14.67
- Technical
- Relative Strength Index (RSI)
- APVO 28.32
- ENSC 49.99
- Support Level
- APVO $4.30
- ENSC $2.12
- Resistance Level
- APVO $5.18
- ENSC $2.57
- Average True Range (ATR)
- APVO 1.22
- ENSC 0.21
- MACD
- APVO 0.72
- ENSC 0.04
- Stochastic Oscillator
- APVO 6.47
- ENSC 53.87
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
About ENSC Ensysce Biosciences Inc.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.